journal
https://read.qxmd.com/read/38885678/peptic-ulcer-disease
#1
REVIEW
Majid A Almadi, Yidan Lu, Ali A Alali, Alan N Barkun
Annual prevalence estimates of peptic ulcer disease range between 0·12% and 1·5%. Peptic ulcer disease is usually attributable to Helicobacter pylori infection, intake of some medications (such as aspirin and non-steroidal anti-inflammatory medications), or being critically ill (stress-related), or it can be idiopathic. The clinical presentation is usually uncomplicated, with peptic ulcer disease management based on eradicating H pylori if present, the use of acid-suppressing medications-most often proton pump inhibitors (PPIs)-or addressing complications, such as with early endoscopy and high-dose PPIs for peptic ulcer bleeding...
June 14, 2024: Lancet
https://read.qxmd.com/read/38880110/department-of-error
#2
(no author information available yet)
No abstract text is available yet for this article.
June 13, 2024: Lancet
https://read.qxmd.com/read/38880109/protecting-the-blood-donor-ferritin-based-intervals-to-improve-donor-health
#3
JOURNAL ARTICLE
Laura Infanti
No abstract text is available yet for this article.
June 13, 2024: Lancet
https://read.qxmd.com/read/38880108/effectiveness-of-ferritin-guided-donation-intervals-in-whole-blood-donors-in-the-netherlands-find-em-a-stepped-wedge-cluster-randomised-trial
#4
JOURNAL ARTICLE
Amber Meulenbeld, Steven Ramondt, Maike G Sweegers, Franke A Quee, Femmeke J Prinsze, Emiel O Hoogendijk, Dorine W Swinkels, Katja van den Hurk
BACKGROUND: Whole-blood donors are at increased risk for iron deficiency and anaemia. The current standard of haemoglobin monitoring is insufficient to ensure the maintenance of proper iron reserves and donor health. We aimed to determine the effects of ferritin-guided donation intervals for blood donor health and blood supply in the Netherlands. METHODS: In this stepped-wedge cluster-randomised trial (FIND'EM), the 138 fixed and mobile donation centres in the Netherlands are organised into 29 geographical clusters and the clusters were randomly assigned to four treatment groups, with two groups being further split into two per a protocol amendment...
June 13, 2024: Lancet
https://read.qxmd.com/read/38880107/a-programme-for-greater-health-equity-for-the-next-uk-government
#5
JOURNAL ARTICLE
Michael Marmot, Jessica Allen
No abstract text is available yet for this article.
June 13, 2024: Lancet
https://read.qxmd.com/read/38876135/neoadjuvant-therapy-for-oesophageal-cancer-refining-the-armamentarium
#6
JOURNAL ARTICLE
Salah-Eddin Al-Batran, Christine Koch
No abstract text is available yet for this article.
June 11, 2024: Lancet
https://read.qxmd.com/read/38876134/radiotherapy-for-anti-vascular-endothelial-growth-factor-injections-for-neovascular-age-related-macular-degeneration
#7
JOURNAL ARTICLE
Gui-Shuang Ying, Brian L VanderBeek
No abstract text is available yet for this article.
June 11, 2024: Lancet
https://read.qxmd.com/read/38876133/doublet-chemotherapy-triplet-chemotherapy-or-doublet-chemotherapy-combined-with-radiotherapy-as-neoadjuvant-treatment-for-locally-advanced-oesophageal-cancer-jcog1109-next-a-randomised-controlled-open-label-phase-3-trial
#8
JOURNAL ARTICLE
Ken Kato, Ryunosuke Machida, Yoshinori Ito, Hiroyuki Daiko, Soji Ozawa, Takashi Ogata, Hiroki Hara, Takashi Kojima, Tetsuya Abe, Takeo Bamba, Masaya Watanabe, Hirofumi Kawakubo, Yuichi Shibuya, Yasuhiro Tsubosa, Naoki Takegawa, Takeshi Kajiwara, Hideo Baba, Masaki Ueno, Hiroya Takeuchi, Kenichi Nakamura, Yuko Kitagawa
BACKGROUND: Neoadjuvant therapy is the standard treatment for patients with locally advanced oesophageal squamous cell carcinoma (OSCC). However, the prognosis remains poor and more intensive neoadjuvant treatment might be needed to improve patient outcomes. We therefore aimed to compare the efficacy and safety of neoadjuvant doublet chemotherapy, triplet chemotherapy, and doublet chemotherapy plus radiotherapy in patients with previously untreated locally advanced OSCC. METHODS: In this randomised, open-label, phase 3 trial, patients aged 20-75 years with previously untreated locally advanced OSCC and an Eastern Cooperative Oncology Group performance status of 0 or 1 were recruited from 44 centres across Japan...
June 11, 2024: Lancet
https://read.qxmd.com/read/38876132/stereotactic-radiotherapy-for-neovascular-age-related-macular-degeneration-star-a-pivotal-randomised-double-masked-sham-controlled-device-trial
#9
JOURNAL ARTICLE
Timothy L Jackson, Riti Desai, Hatem A Wafa, Yanzhong Wang, Janet Peacock, Tunde Peto, Usha Chakravarthy, Helen Dakin, Sarah Wordsworth, Cornelius Lewis, Patricia Clinch, Lisa Ramazzotto, James E Neffendorf, Chan Ning Lee, Joe M O'Sullivan, Barnaby C Reeves
BACKGROUND: Neovascular age-related macular degeneration (nAMD) is a leading cause of blindness. The first-line therapy is anti-vascular endothelial growth factor (anti-VEGF) agents delivered by intravitreal injection. Ionising radiation mitigates key pathogenic processes underlying nAMD, and therefore has therapeutic potential. STAR aimed to assess whether stereotactic radiotherapy (SRT) reduces the number of anti-VEGF injections required, without sacrificing visual acuity. METHODS: This pivotal, randomised, double-masked, sham-controlled trial enrolled participants with pretreated chronic active nAMD from 30 UK hospitals...
June 11, 2024: Lancet
https://read.qxmd.com/read/38857611/long-term-colchicine-for-the-prevention-of-vascular-recurrent-events-in-non-cardioembolic-stroke-convince-a-randomised-controlled-trial
#10
JOURNAL ARTICLE
Peter Kelly, Robin Lemmens, Christian Weimar, Cathal Walsh, Francisco Purroy, Mark Barber, Ronan Collins, Simon Cronin, Anna Czlonkowska, Philippe Desfontaines, Adinda De Pauw, Nicholas Richard Evans, Urs Fischer, Catarina Fonseca, John Forbes, Michael D Hill, Dalius Jatuzis, Janika Kõrv, Peter Kraft, Christina Kruuse, Catherine Lynch, Dominick McCabe, Robert Mikulik, Sean Murphy, Paul Nederkoorn, Martin O'Donnell, Peter Sandercock, Bernadette Schroeder, Gek Shim, Katrina Tobin, David J Williams, Christopher Price
BACKGROUND: Anti-inflammatory therapy with long-term colchicine prevented vascular recurrence in coronary disease. Unlike coronary disease, which is typically caused by atherosclerosis, ischaemic stroke is caused by diverse mechanisms including atherosclerosis and small vessel disease or is frequently due to an unknown cause. We aimed to investigate the hypothesis that long-term colchicine would reduce recurrent events after ischaemic stroke. METHODS: We did a randomised, parallel-group, open-label, blinded endpoint assessed trial comparing long-term colchicine (0·5 mg orally per day) plus guideline-based usual care with usual care only...
June 7, 2024: Lancet
https://read.qxmd.com/read/38857610/colchicine-for-the-prevention-of-vascular-events-after-non-cardioembolic-stroke
#11
JOURNAL ARTICLE
Aristeidis H Katsanos, Ashkan Shoamanesh
No abstract text is available yet for this article.
June 7, 2024: Lancet
https://read.qxmd.com/read/38852600/burr-hole-drainage-with-or-without-irrigation-for-chronic-subdural-haematoma-finish-a-finnish-nationwide-parallel-group-multicentre-randomised-controlled-non-inferiority-trial
#12
JOURNAL ARTICLE
Rahul Raj, Pihla Tommiska, Timo Koivisto, Ville Leinonen, Nils Danner, Jussi P Posti, Dan Laukka, Teemu Luoto, Minna Rauhala, Sami Tetri, Tommi K Korhonen, Jarno Satopää, Riku Kivisaari, Teemu Luostarinen, Christoph Schwartz, Tomasz Czuba, Simo Taimela, Kimmo Lönnrot, Teppo L N Järvinen
BACKGROUND: Chronic subdural haematoma is a common surgically treated intracranial emergency. Burr-hole drainage surgery, to evacuate chronic subdural haematoma, involves three elements: creation of a burr hole for access, irrigation of the subdural space, and insertion of a subdural drain. Although the subdural drain has been established as beneficial, the therapeutic effect of subdural irrigation has not been addressed. METHODS: The FINISH trial was an investigator-initiated, pragmatic, multicentre, nationwide, randomised, controlled, parallel-group, non-inferiority trial in five neurosurgical units in Finland that enrolled adults aged 18 years or older with a chronic subdural haematoma requiring burr-hole drainage...
June 6, 2024: Lancet
https://read.qxmd.com/read/38852599/optimising-treatment-for-chronic-subdural-haematoma
#13
JOURNAL ARTICLE
Keita Shibahashi
No abstract text is available yet for this article.
June 6, 2024: Lancet
https://read.qxmd.com/read/38851205/the-role-of-caregivers-in-mental-health-and-child-development-policy-and-practice
#14
JOURNAL ARTICLE
Tracey Smythe, Julian Eaton, Adanech Abiebie, Andrea Hernandez Arriaga, Emily Miner
No abstract text is available yet for this article.
June 5, 2024: Lancet
https://read.qxmd.com/read/38851204/the-developing-role-of-theranostics-in-nets
#15
JOURNAL ARTICLE
Robert A Ramirez, Cathy Eng
No abstract text is available yet for this article.
June 5, 2024: Lancet
https://read.qxmd.com/read/38851203/-177-lu-lu-dota-tate-plus-long-acting-octreotide-versus-high%C3%A2-dose-long-acting-octreotide-for-the-treatment-of-newly-diagnosed-advanced-grade-2-3-well-differentiated-gastroenteropancreatic-neuroendocrine-tumours-netter-2-an-open-label-randomised-phase-3-study
#16
JOURNAL ARTICLE
Simron Singh, Daniel Halperin, Sten Myrehaug, Ken Herrmann, Marianne Pavel, Pamela L Kunz, Beth Chasen, Salvatore Tafuto, Secondo Lastoria, Jaume Capdevila, Amparo García-Burillo, Do-Youn Oh, Changhoon Yoo, Thorvardur R Halfdanarson, Stephen Falk, Ilya Folitar, Yufen Zhang, Paola Aimone, Wouter W de Herder, Diego Ferone
BACKGROUND: There are currently no standard first-line treatment options for patients with higher grade 2-3, well-differentiated, advanced, gastroenteropancreatic neuroendocrine tumours. We aimed to investigate the efficacy and safety of first-line [177 Lu]Lu-DOTA-TATE (177 Lu-Dotatate) treatment. METHODS: NETTER-2 was an open-label, randomised, parallel-group, superiority, phase 3 trial. We enrolled patients (aged ≥15 years) with newly diagnosed higher grade 2 (Ki67 ≥10% and ≤20%) and grade 3 (Ki67 >20% and ≤55%), somatostatin receptor-positive (in all target lesions), advanced gastroenteropancreatic neuroendocrine tumours from 45 centres across nine countries in North America, Europe, and Asia...
June 5, 2024: Lancet
https://read.qxmd.com/read/38851202/department-of-error
#17
(no author information available yet)
No abstract text is available yet for this article.
June 5, 2024: Lancet
https://read.qxmd.com/read/38848739/aftercare-for-surgically-treated-ankle-fractures
#18
JOURNAL ARTICLE
Tim Schepers, Jens A Halm
No abstract text is available yet for this article.
June 4, 2024: Lancet
https://read.qxmd.com/read/38848738/early-versus-delayed-weight-bearing-following-operatively-treated-ankle-fracture-wax-a-non-inferiority-multicentre-randomised-controlled-trial
#19
JOURNAL ARTICLE
Christopher Patrick Bretherton, Juul Achten, Vidoushee Jogarah, Stavros Petrou, Nicholas Peckham, Felix Achana, Duncan Appelbe, Rebecca Kearney, Harry Claireux, Philip Bell, Xavier L Griffin
BACKGROUND: After surgery for a broken ankle, patients are usually instructed to avoid walking for 6 weeks (delayed weight-bearing). Walking 2 weeks after surgery (early weight-bearing) might be a safe and preferable rehabilitation strategy. This study aimed to determine the clinical and cost effectiveness of an early weight-bearing strategy compared with a delayed weight-bearing strategy. METHODS: This was a pragmatic, multicentre, randomised, non-inferiority trial including 561 participants (aged ≥18 years) who received acute surgery for an unstable ankle fracture in 23 UK National Health Service (NHS) hospitals who were assigned to either a delayed weight-bearing (n=280) or an early weight-bearing rehabilitation strategy (n=281)...
June 4, 2024: Lancet
https://read.qxmd.com/read/38843860/vimseltinib-versus-placebo-for-tenosynovial-giant-cell-tumour-motion-a-multicentre-randomised-double-blind-placebo-controlled-phase-3-trial
#20
JOURNAL ARTICLE
Hans Gelderblom, Vivek Bhadri, Silvia Stacchiotti, Sebastian Bauer, Andrew J Wagner, Michiel van de Sande, Nicholas M Bernthal, Antonio López Pousa, Albiruni Abdul Razak, Antoine Italiano, Mahbubl Ahmed, Axel Le Cesne, Gabriel Tinoco, Kjetil Boye, Javier Martín-Broto, Emanuela Palmerini, Salvatore Tafuto, Sarah Pratap, Benjamin C Powers, Peter Reichardt, Antonio Casado Herráez, Piotr Rutkowski, Christopher Tait, Fiona Zarins, Brooke Harrow, Maitreyi G Sharma, Rodrigo Ruiz-Soto, Matthew L Sherman, Jean-Yves Blay, William D Tap
BACKGROUND: Tenosynovial giant cell tumour (TGCT) is a locally aggressive neoplasm for which few systemic treatment options exist. This study evaluated the efficacy and safety of vimseltinib, an oral, switch-control, CSF1R inhibitor, in patients with symptomatic TGCT not amenable to surgery. METHODS: MOTION is a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial done in 35 specialised hospitals in 13 countries. Eligible patients were adults (aged ≥18 years) with a histologically confirmed diagnosis of TGCT for which surgical resection could potentially worsen functional limitation or cause severe morbidity...
May 31, 2024: Lancet
journal
journal
20186
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.